A Pilot Trial of Atorvastatin in Tumor Protein 53 (p53) -Mutant and p53 Wild-Type Malignancies
Status:
Recruiting
Trial end date:
2025-08-01
Target enrollment:
Participant gender:
Summary
This is a window-of-opportunity trial to determine if atorvastatin given for 1 to 4 weeks at
a dose of 80 milligrams per day (mg/day) is sufficient to decrease the level of
conformational mutant tumor protein 53 (p53) in malignant diseases (solid tumor and relapsed
Acute Myeloid Leukemia (AML)).